| Name | Title | Contact Details |
|---|
Wellness programs are out. Wellbeing strategies are in. To thrive today, organizations must be trustworthy while nurturing a culture where people do their best work. There’s no shortcut to true potential, but CHC has a proven roadmap to reduce benchmar...
UC San Diego Health Sciences has long been known as a place where discoveries are made. Today, we are known as a place where discoveries are delivered. UC San Diego Health Sciences encompasses the School of Medicine, the Skaggs School of Pharmacy and Pharmaceutical Sciences, and UC San Diego Health System, including UC San Diego Medical Center, in Hillcrest; and in La Jolla, Thornton Hospital, Moores Cancer Center, Sulpizio Cardiovascular Center; and other centers, primary and specialty practices of the UC San Diego Medical Group faculty physicians. As a top-tier academic medical center, its role is to provide leadership in improving health through research, education and patient care. UC San Diego Health Sciences has long been at the forefront of “bench-to-bedside” research, transforming patient care through discovery and innovation leading to new drugs and technologies. It is carried out every day in the hundreds of clinical trials of promising new therapies offered through UC San Diego Health System, and in the drive of our researchers and clinician-scientists who are committed to having a significant impact on patient care. At UC San Diego Health Sciences, there are many discoveries on our horizon. Our commitment is to continue our quest to cure disease, seek better treatments and train the next generation of physicians and scientists.
Emerging leader in prescription digital therapeutics
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
NovaRx Corporation is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. NovaRx Corporation is based in San Diego, CA. You can find more information on NovaRx Corporation at www.novarx.com